Navigation Links
The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016
Date:6/10/2008

Market Will be Driven by Increasing Use of Established Agents That Include Avastin, Erbitux, Rituxan/MabThera, According to a New Report from Decision

Resources

WALTHAM, Mass., June 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the monoclonal antibodies (MAbs) drug market will more than double to $16.7 billion in 2016, driven by the increasing use of currently available therapies that include Roche/Genentech/Chugai's Avastin, Bristol-Myers Squibb/ImClone/Merck KGaA's Erbitux, Genentech/Biogen Idec/Chugai's Rituxan / Roche's MabThera.

The new Pharmacor report entitled Antibody Therapies in Oncology finds that the major driving force behind market growth of the MAbs drug class through 2016 will be the label expansion of currently approved MAbs into other patient populations as well as approvals in new indications in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. In 2006, Avastin held approvals in non-small-cell lung cancer and colorectal cancer -- since that time, of the cancers covered in the report, it has gained approval for breast cancer and renal cell carcinoma and is expected to be approved for prostate cancer and ovarian cancer. Avastin's applicability across multiple tumor types, even if it sees only limited patient share in some indications, is key to its success.

While not as successful as Avastin in terms of revenue generation or its use across as many tumor types, Erbitux generates significant sales in colorectal cancer and squamous cell carcinoma of the head and neck. Also, Erbitux is expected to be approved for the treatment of non-small-cell lung cancer, which will dramatically boost its sales. Lastly, although the use of Rituxan/MabThera in non-Hodgkin's lymphoma has reached saturation in many of the subtypes of the disease, this agent is forecasted to gain approval for chronic lymphocytic leukemia, allowing for increased prescribing in Europe where the cost-constrained environment limits off-label use.

Market sales will also be driven by the introduction of four new MAbs by 2016: Genmab/GlaxoSmithKline's ofatumumab for non-Hodgkin's lymphoma and chronic lymphocytic leukemia, Medarex/Bristol-Myers Squibb's ipilimumab for malignant myeloma, Genmab's zanolimumab for T-cell lymphoma, and Genentech/Roche/Chugai's pertuzumab for breast cancer.

"These emerging MAbs will contribute significant sales by 2016," said Clair Gricks, Ph.D., analyst at Decision Resources, "They will provide new therapeutic options for patients with currently limited choices or will improve the efficacy of established agents when used in combination. The majority of market growth, however, will be driven by label expansions and increased uptake of currently marketed MAbs."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product
2. Monoclonal antibody Hb3: A marker for colon cancer progression or as a therapeutic target?
3. Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies.
4. Scripps Research scientists shed new light on how antibodies fight HIV
5. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
6. Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring
7. Autoantibodies and neuropsychiatric events in lupus
8. Vegan diet promotes atheroprotective antibodies in patients with rheumatoid arthritis
9. Anti-HAV antibodies in beta-thalassemia
10. Researchers Develop Quick Way to Create Human Antibodies
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... professionals, announced today its affiliation with Tennessee Counseling Association. This new ... network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , ...
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: